A Phase 1/2 Multicenter, Randomized, Controlled Dose-Finding Study to Evaluate the Safety and Ocular Hypotensive Efficacy of 3 Dose Levels of the VS101 Subconjunctival Latanoprost Insert for 3 Months in Subjects With Open-Angle Glaucoma or Ocular Hypertension

Trial Profile

A Phase 1/2 Multicenter, Randomized, Controlled Dose-Finding Study to Evaluate the Safety and Ocular Hypotensive Efficacy of 3 Dose Levels of the VS101 Subconjunctival Latanoprost Insert for 3 Months in Subjects With Open-Angle Glaucoma or Ocular Hypertension

Active, no longer recruiting
Phase of Trial: Phase I/II

Latest Information Update: 24 Jul 2017

At a glance

  • Drugs Latanoprost (Primary)
  • Indications Glaucoma
  • Focus First in man; Therapeutic Use
  • Sponsors ViSci
  • Most Recent Events

    • 24 Jul 2017 Results of Eye-D latanoprost inserts published in the BioLight Life Sciences Ltd media release.
    • 18 Apr 2017 Status changed from recruiting to active, no longer recruiting.
    • 31 Oct 2016 Planned End Date changed from 1 Jun 2016 to 1 Aug 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top